Sharing takeaways and recs from recent reading blocks.
Who would I recommend this to?
๐ Everyone
๐ Any interest in topic
๐๏ธ You often read on this topic
๐ Nah
Michelin, not Amazon, style ratings = any non-๐ is a good book.
๐
Keynes Hayek by @NWapshott
Topic: ๐๐ฐ
Layperson's history of JM Keynes' inventing #macroeconomics, and opposition by ppl who fear inflation > unemployment.
โข #Stimulus packages are <100y old
โข They seem like magic, but aren't
โข Fiscal policy goes beyond red vs blue
๐๏ธ
The Snowball by @aliceschroeder
Topic ๐ฐ๐
Great bio, but #Buffett's life is so consistent most ppl won't need 700 pages of it.
โข "Take a simple idea, and take it very seriously"
โข Learned early he loves making money, never stopped
โข Wife surely made him a better human
๐
[See pic] by John Bogle
Topic ๐ฐ๐
Bogle invented index funds, tells you why they're great. He's not wrong, but this could have been 1-2 pages.
โข Most people can't beat average returns
โข Mutual funds' fees pull them below the average
โข Embrace the average, at 0.01% fees
โข Make plans far removed from scenarios they cover
โข Stick to plans!
โข Post-mortem on process, not outcomes
๐๏ธ
Biohazard by Ken Alibek
Topic ๐ฆ ๐ฃ
Memoir of running #Soviet#ColdWar#biioweapons programs. Politics, history, and gory details of #pathogens.
โข VERY active programs, despite treaties
โข Paranoid politics ruled everything
โข Viruses/bacteria are engineerable, but not easily
๐น
Plague Time by Paul Ewald
Topic ๐ฆ ๐ฅ
Torn on this one. Message is important, but author's indignant tone is frustrating...
โข Not all #InfectiousDisease is acute.
โข Many ๐ฆ are linked to #ChronicDisease, eg schizophrenia and cancer.
โข We stopped studying this in the 70s.
๐
Parable of the Sower by Octavia Butler
A special book, to mark the date: Eerily prescient tale of a girl's decision to take control, in a 2025 of ๐ warming, indifferent ๐ฎ, racism, lawlessness and societal decline. Shape yourself, to shape Destiny and populate the stars.
Written in 1993, it feels like turning on the news today. Heck, the sequel has a white supremacist campaigning for president to "Make America Great Again"...
The writing is exquisite for any genre, and the message in the protagonist's personal religion is profound and important.
๐๏ธ
The Coming Plague by @Laurie_Garrett
Topic ๐๐ฆ
A (scholarly and nuanced) beast! 600 pages of deadly epidemics and the scientists who fought them.
โข New microbes appear 'out of nowhere'
โข Environmental and demographic shifts contribute
โข Pandemics spread thru early denial
๐๐ผ @drperszyk for suggesting '๐ blocks' of 3-4 ๐ to better chart a subject.
Main #InfectiousDisease takeaway:
I'm surprised that I'm surprised by the artificial divide between infectious and other disease/biology.
Next ๐ would be on #Microbiome, but field still too nascent.
๐๏ธ
The Effective Executive by Peter Drucker
Topic ๐จโ๐ผ
In a genre of 1-page ideas backed by 199 pages of anecdotes, this one is actually good. Even so, Pareto readers will prefer Drucker's essay summary: hbr.org/2004/06/what-mโฆ, which I will let substitute for my summary bullets
โข Conscious self-talk is a barrier to execution
โข Focus quiets consciousness, needs practice
โข Focus in tennis(/xyz), to improve focus
๐
Superforecasting by @PTetlock
Topic ๐ฎ
Prediction best practices, backed both by long ๐จโ๐ฌ career and @IARPAnews competition wins.
โข Base rates, then unique case
โข "Probably" โก๏ธ "67%"
โข New info โก๏ธ Frequent but minor updates
โข Forecasting works mid (6mo) not long (5y) term
๐
[...] Leadership Mindtraps by @jgberger
Topic ๐ง ๐ชค
Nice summary of some "True Simple Things". High usefulness/page, several actionable methods.
โข See >1 story describing each situation
โข Dodge need for control by looking to enable
โข Who you "are" now is not permanent
Summary of "thought traps" reading block:
โข Biz books ARE full of obvious advice, but SOMETIMES that's needed in the middle of doing hard things
โข As evidenced by... life, putting Simple Truths into practice is hard
โข Bar for quality is very high, quantity is actively harmful
I'm also realizing that I should have chosen different icons for my ratings, since they're about whom I'd recommend to rather than quality.
Some of these books are excellent but quite specific, thus get a๐๏ธ. Alas, hopefully nobody gets offended.
๐๏ธ
[See pic] by @PeterKolchinsky
Topic ๐ฅ๐ต
Great explanation of dynamics between healthcare costs, biotech, and societal benefit.
โข $$$ drugs later grow our pool of cheap generics
โข Reported prices aren't real, insurance gets big discounts
โข Lower prices can't fix co-pays
@PeterKolchinsky ๐
Malignant by @VPrasadMDMPH
Topic ๐ฆ๐ฅ
Blew my mind re. how cancer drugs get approved. Hint: it's a mess.
โข Surrogate endpoints (eg tumor shrinks) over(ab)used
โข Control arms not always std of care, esp post-protocol
โข Economics = Ph3 after failed Ph2 can have positive๐ฒEV
A clarification: the only reason this didn't get a 'recommend to anyone curious about topic' rating is the word count. Quality is unparalleled.
๐
Bottle of Lies by @KatherineEban
Topic ๐โ ๏ธ
Hard to believe this is real; Theranos-level fraud for generic drugs we all take.
โข Generics not all equal, or safe
โข FDA often can't inspect non-US suppliers, but we still get their drugs
โข Jugaad = creatively removing obstacles
Drug/#healthcare block lessons:
โข I'd assumed that FDA approval = infallible ground truth on safety and efficacy, but FDA is described as understaffed and sometimes under political pressure at odds with the core mission (even before 2016). Still absolutely crucial organization.
โข A lot of issues in US #Healthcare costs are from conflicts between utilitarian analysis (=don't pay for $$$ drug that's marginally effective) and the emotional narratives ("Senator X wants cancer patients to die!"), from Congress to your family doctor.
โข Advertising works...
โข Does not seem that most #biopharma act on pure greed, maybe slightly less so than other S&P500. But do act to profit within incentive structures they're subject to.
Tension from ppl feeling entitled to drug dev and #healthcare, but it being "responsibility" of private corps.
Two days after I posted this I see the following ad ๐ค
Even though I work on making non-#generic drugs, they're not a bad thing! As long as they're actually equivalent...
โข โข โข
Missing some Tweet in this thread? You can try to
force a refresh
I'm struggling to wrap my head around the new Weissman lab myHSC depletion paper:
The first authors don't seem to be on twitter but hoping I can crowdsource a fun discussion. @dbgoodman @ImmunoFever @Jeff_Mold @Satpathology @CalebLareau...nature.com/articles/s4158โฆ
The premise of the paper is that immune function declines with age in part because a haematopoetic stem cell (HSC) population skewed towards myeloid lineage increases in prevalence, and that targeting this population with antibodies can restore function. Cool idea!
โ1โฃ: How well defined are myHSCs?
Here myHSC seems to be defined as CD150 high, based mainly on Beerman 2010 .
But looking at Figure 3, CD150 expression is a continuous distribution. Is this a clear cell population with somewhat understood behavior? pnas.org/doi/full/10.10โฆ
If you want to build a career in biotech, should you get a PhD after college or join a company directly (as a Research Associate/RA, usually)?
There's no single answer, but I have the conversation often enough that I thought I'd share some pros/cons... (1/n)
First, see this thread about different types of biopharma companies. For reasons I'll get into, I think early stage (probably founder led) biotech is your best bet unless you still want to do PhD later.
(PS if you want to be a professor, it's ๐ฏ PhD) 2/n
PhD will give you more options.
Some companies (incl. @GordianBio) will help you grow from RA to Scientist role (and beyond). But many, esp larger, companies have a glass ceiling if you don't have a PhD. Even if you pick one w/o glass ceiling, you'll be worse off it if fails. 3/n
All these points resonate, for early stage biotech at least. @erlichya touches on this, but I think worth separating "industry" into different clusters that will feel quite different to someone coming from academia (still oversimplified, of course):
Pharma (eg Pfizer) vs biotech:
You wear fewer hats, see less of the company but company as a whole spans wider range of expertise, fewer changes in direction, often higher income but no chance of getting rich. Both have job insecurity: pharma doesn't go die but programs do.
Clinical vs R&D stage biotech:
Clinical may still have R&D but it's no longer the biggest driver of success vs failure. Assay validation/rigor > assay development/invention. Clinical can feel more like pharma, but with more urgency/stakes: one program = life or death of co.
#SciTwitter After a lot of research and asking around, I'm making the lab equipment recommendations ๐งต I wish I'd had 2 months ago. RT/share with a #newPI or startup ๐ฌโ๏ธ๐
Note, much of the equipment hasn't arrived yet, will add comments after actual use.
-20 #freezer
Less clear, many viable options. We ended up getting a split of PHC MDF -30 (recommended as quieter) and much cheaper Corepoint Scientific/@VWR, will see which we prefer. Thermo hasn't failed #MBCbiolabs, but $$$ and several people said poor customer support.
As with all experiments, I expect that some of these will disappear and that others will be a central part of science in ten years.
But them happening at all is enough to renew a conversation about how science is funded and conducted.
๐ฆธ๐ฝ While I've been doing most of the tweeting, the Longevity Apprentices @LNuzhna@kush__sharma@edmarferreira & Tara Mei are the real heroes for running the operations.
This has been a great Apprenticeship project, merging action and exposure to research martinborchjensen.com/apprenticeship
๐ The review + awards process was fairly smooth, thanks in part to @kush__sharma's custom reviewer UI. Several reviewers told us unprompted that it was their best review experience ever; the UI took 2 wks to make, so there's low hanging fruit for other agencies in that area.